Industry News
Biotechnology Industry News
AstraZeneca is taking its oral…
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the drug actually performed.
AstraZeneca executives have told…
AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure despite abandoning work on one of two clinical-stage candidates.
Kailera Therapeutics and its China…
Kailera Therapeutics and its China partner Hengrui have released top-line results from a phase 2 trial of their oral version of ribupatide that indicate it has a “potentially game-changing clinical profile,” according to Kailera’s chief medical
OrsoBio’s experimental oral drug…
OrsoBio’s experimental oral drug lowered fasting triglyceride levels at four weeks of treatment, hitting the primary efficacy goal in a midstage study of metabolic conditions.
After facing a delayed decision…
After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by the FDA.
Eli Lilly has become the latest…
Eli Lilly has become the latest Big Pharma to buy itself into a corner of the in vivo CAR-T space via the acquisition of Orna for up to $2.4 billion.
Roche has shared the numbers…
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis, linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to Ocrevus.
Eli Lilly is heading back to its…
Eli Lilly is heading back to its regular Chinese collaborator Innovent with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders.
Ever since 6-year-old Emily…
Ever since 6-year-old Emily Whitehead became the first patient to receive CAR-T cell therapy in 2012, where T cells were removed from her body and reprogrammed to attack her leukemia before being reinfused, drug developers
Takeda and Iambic Therapeutics…
Takeda and Iambic Therapeutics have agreed to a multiyear technology and discovery agreement that'll leverage Iambic’s broad suite of AI-driven drug discovery platforms. The agreement gives Iambic the chance to earn up to $1.7 billion.
ILiAD Biotechnologies Inc….
ILiAD Biotechnologies Inc. announced the close of an oversubscribed $115 million series B fund raise this week to support the company’s next generation pertussis (whooping cough) vaccine candidate.
On top of 348 known job cuts…
On top of 348 known job cuts across the organization last year, Genentech laid off an additional 141 staffers last August that are just now being disclosed.
The deal allows CSL to potentially…
The deal allows CSL to potentially exercise an option on recombinant polyclonal immunoglobulin products that could grant Memo up to $328 million on sales milestones.
Two dose-limiting toxicities have…
Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to treat the rare condition Fabry disease.
Belgian biotech Agomab…
Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this morning as momentum continues to build for biopharma IPOs.
As Priovant works toward approval…
As Priovant works toward approval of potential blockbuster brepocitinib as a treatment for dermatomyositis, the North Carolina biotech has presented promising results for the TYK2/JAK1 inhibitor in another rare skin condition.
Angitia Biopharmaceuticals has…
Angitia Biopharmaceuticals has unveiled its second mega-round in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the clinic.
Clinical-stage antibody company…
Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build.
Quell Therapeutics is pressing…
Quell Therapeutics is pressing pause on an engineered regulatory T-cell therapy for liver transplant patients in order to focus resources on a preclinical autoimmune candidate.
Bayer has linked asundexian to a…
Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.